Erratum (DOI:10.1016/j.amepre.2007.10.003);Screening for Prostate Cancer in U.S. Men. ACPM Position Statement on Preventive Practice

American Journal of Preventive Medicine

Volumn 34, Issue 2, 2008, Pages 164-170

  Lim, Lionel S ^a   Sherin, Kevin ^b  

^a Griffin Hospital   (United Kingdom)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH HAZARD; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; MEDICAL DECISION MAKING; MORBIDITY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES;

EID: 38049031795     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2008.02.008     Document Type: Erratum

References (60)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2004), National Cancer Institute (NCI), DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. Available online at: www.seer.cancer.gov.
3. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U.S. (1969-2004), NCI, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Available online at: www.seer.cancer.gov.
4. NCI. SEER*Stat Database: Incidence-SEER 17 Regs Public-Use, Nov 2005 Sub (1973-2003 varying) April 2006 (based on the November 2005 submission). Available online at: www.seer.cancer.gov.
5. Haas G.P., and Sakr W.A. Epidemiology of prostate cancer. CA Cancer J Clin 47 (1997) 273-287
6. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
7. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283-1290
8. Lubke W.L., Optenberg S.A., and Thompson I.M. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst 86 (1994) 1790-1792
9. Vihko P., Kontturi M., Lukkarinen O., Ervasti J., and Vihko R. Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared. Cancer 56 (1985) 173-177
10. Chodak G.W., Keller P., and Schoenberg H.W. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141 (1989) 1136-1138
11. Schroder F.H., Denis L.J., Roobol M., et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 92 Suppl 2 (2003) 1-13
12. Jacobsen S.J., Bergstralh E.J., Katusic S.K., et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 52 (1998) 173-179
13. Friedman G.D., Hiatt R.A., Quesenberry Jr. C.P., and Selby J.V. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 337 (1991) 1526-1529
14. Richert-Boe K.E., Humphrey L.L., Glass A.G., and Weiss N.S. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 5 (1998) 99-103
15. Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 (2004) 311-318
16. Sandblom G., Varenhorst E., Lofman O., Rosell J., and Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 46 (2004) 717-723 discussion 24
17. Ilic D., O'Connor D., Green S., and Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 3 (2006) CD004720
18. Aus G., Bergdahl S., Lodding P., Lilja H., and Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol 51 (2007) 659-664
19. Schroder F.H., Habbema D.F., Roobol M.J., and Bangma C.H. Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction. Eur Urol 51 (2007) 588-590
20. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol 174 (2005) 121-125
21. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438
22. Ross L.E., Coates R.J., Breen N., Uhler R.J., Potosky A.L., and Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 38 (2004) 732-744
23. Presti J., McNeal J., Hsu T., Brooks J., and Gill H. Performance of PSA levels between 4 and 10 ng/mL in the era of extended biopsy schemes. Program and abstracts of the American Urological Association 2006 Annual Meeting (2006) May 20-25; Atlanta GA. Abstract 468
24. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
25. Hakama M., Stenman U.H., Aromaa A., Leinonen J., Hakulinen T., and Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 166 (2001) 2189-2191 discussion 91-2
26. Loeb S., Roehl K.A., Antenor J.A., Catalona W.J., Suarez B.K., and Nadler R.B. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316-320
27. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
28. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
29. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23 (2005) 4975-4979
30. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
31. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
32. Loeb S., Roehl K.A., Catalona W.J., and Nadler R.B. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177 (2007) 899-902
33. American Cancer Society. Can prostate cancer be found early? (2007). http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_prostate_cancer_be_found_early_36.asp Available online at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_prostate_cancer_be_found_early_36.asp
34. Lee R., Localio A.R., Armstrong K., Malkowicz S.B., and Schwartz J.S. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67 (2006) 762-768
35. Smith L.F. Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol 96 (2007) 451-452
36. Crawford E.D. Prostate Cancer Awareness Week: September 22 to 28, 1997. CA Cancer J Clin 47 (1997) 288-296
37. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
38. Ransohoff D.F., Lang C.A., and American College of Physicians. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med 126 (1997) 811-822
39. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
40. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
41. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
42. Saigal C.S., and Litwin M.S. The economic costs of early stage prostate cancer. Pharmacoeconomics 20 (2002) 869-878
43. McNaughton-Collins M., Fowler Jr. F.J., Caubet J.F., et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 117 (2004) 719-725
44. Cantor S.B., Volk R.J., Cass A.R., Gilani J., and Spann S.J. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect 5 (2002) 104-113
45. Catalona W.J., Antenor J.A., Roehl K.A., and Moul J.W. Screening for prostate cancer in high risk populations. J Urol 168 (2002) 1980-1983 discussion 3-4
46. Gwede C.K., and McDermott R.J. Prostate cancer screening decision making under controversy: implications for health promotion practice. Health Promot Pract 7 (2006) 134-146
47. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
48. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 14 (2000) 267-272 77-8, 80 passim
49. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56 (2006) 11-25 quiz 49-50
50. American Academy of Family Physicians (AAFP). Summary of recommendations for clinical preventive services. Revision 6.0 (2005), American Academy of Family Physicians (AAFP), Leawood KS August
51. Institute for Clinical Systems Improvement (ICSI). Preventive services in adults (2005), ICSI, Bloomington MN October
52. U.S. Preventive Services Task Force (USPSTF). Screening for prostate cancer: recommendation and rationale. Ann Intern Med 137 (2002) 915-916
53. American College of Physicians (AFP). Screening for prostate cancer. Ann Intern Med 126 (1997) 480-484
54. Feightner J.W. Screening for prostate cancer. Canadian Task Force on the Periodic Health Examination Canadian Guide to Clinical Preventive Health Care (1994), Health Canada, Ottawa 812-823
55. Prostate cancer. Available online at: http://www.nlm.nih.gov/medlineplus/prostatecancer.html.
56. Prostate cancer screening: Should you get a PSA test? Available online at: http://www.mayoclinic.com/health/prostate-cancer/HQ01273.
57. Prostate Cancer: Screening. Available online at: http://www.cancer.gov/cancerinfo/pdq/screening/prostate/.
58. Prostate Cancer Screening: A Decision Guide. Available online at: http://www.cdc.gov/cancer/prostate/publications/decisionguide/.
59. Prostate Cancer Screening: A Decision Guide for African Americans. Available online at: http://www.cdc.gov/cancer/prostate/publications/aadecisionguide/.
60. Your disease risk: the source on prevention. Available online at: http://www.yourdiseaserisk.harvard.edu/.